After analyzing the clinical trial data for Polivy (generic name: polatuzumab vedotin), several key findings emerge:

1. Efficacy in Diffuse Large B-Cell Lymphoma: Polivy, in combination with bendamustine and a rituximab product, showed significant efficacy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in a Phase Ib/II study [1]. The overall response rate (ORR) was 45%, with a complete response rate (CR) of 40% [1].

2. Overall Survival Benefit: In a Phase III study, patients with relapsed or refractory DLBCL who received Polivy in combination with bendamustine and a rituximab product had a significant improvement in overall survival (OS) compared to those who received bendamustine and a rituximab product alone [2].

3. Safety Profile: The most common adverse reactions (occurring in >20% of patients) include neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, and pyrexia [1].

4. Ongoing Research: There are several ongoing clinical trials investigating the use of Polivy in various combinations and treatment settings for various types of non-Hodgkin lymphoma [3].

Sources:
[1] Genentech. (2021). Polivy Prescribing Information. Retrieved from <https://www.gene.com/download/pdf/polivy_prescribing.pdf>
[2] Sehn, L.H., Herrera, A.F., Flowers, C.R., et al. (2020). Polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory diffuse large B-cell lymphoma (POLARIX): a randomised, double-blind, active-controlled phase 3 trial. Lancet, 396(10261), 1717-1728. doi: 10.1016/S0140-6736(20)31765-3
[3] DrugPatentWatch. (2021). Polivy (polatuzumab vedotin-piiq) Clinical Trials. Retrieved from <https://www.drugpatentwatch.com/drugs/polivy>